Lumateperone (brand name Caplyta) is a new-generation atypical antipsychotic approved for schizophrenia and bipolar depression. It’s notable for its novel multimodal mechanism and favorable side-effect profile compared to older antipsychotics. | MRCP UK

🧠 Yesterday’s #ClinicalChallenge was: Which of the following statements best reflects the risk of QT interval prolongation associated with haloperidol use? A. Intramuscular haloperidol has been associated with a higher risk of QT prolongation than other formulations. B. Intravenous haloperidol has been associated with a higher risk of QT prolongation than other formulations. C. Haloperidol, regardless of route or dose, does not affect the QT interval and is considered safe for all patients. D.